Rebecca Garris

4.9k total citations
103 papers, 2.1k citations indexed

About

Rebecca Garris is a scholar working on Public Health, Environmental and Occupational Health, Hematology and Genetics. According to data from OpenAlex, Rebecca Garris has authored 103 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 101 papers in Public Health, Environmental and Occupational Health, 68 papers in Hematology and 67 papers in Genetics. Recurrent topics in Rebecca Garris's work include Acute Lymphoblastic Leukemia research (101 papers), Chronic Lymphocytic Leukemia Research (67 papers) and Chronic Myeloid Leukemia Treatments (63 papers). Rebecca Garris is often cited by papers focused on Acute Lymphoblastic Leukemia research (101 papers), Chronic Lymphocytic Leukemia Research (67 papers) and Chronic Myeloid Leukemia Treatments (63 papers). Rebecca Garris collaborates with scholars based in United States, Canada and Japan. Rebecca Garris's co-authors include Hagop M. Kantarjian, Farhad Ravandi, Jörge E. Cortes, Susan O’Brien, Elias Jabbour, Guillermo Garcia‐Manero, Jeffrey L. Jorgensen, Partow Kebriaei, Deborah A. Thomas and Nicholas J. Short and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Rebecca Garris

97 papers receiving 2.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Rebecca Garris United States	19	1.8k	1.4k	922	460	358	103	2.1k
Loredana Elia Italy	18	1.3k 0.7×	1.1k 0.8×	466 0.5×	305 0.7×	263 0.7×	35	1.6k
Deborah Thomas United States	13	760 0.4×	997 0.7×	288 0.3×	176 0.4×	453 1.3×	19	1.3k
Claire Schwab United Kingdom	22	1.5k 0.8×	1.2k 0.8×	217 0.2×	691 1.5×	157 0.4×	46	1.8k
Monica Kwari United States	16	896 0.5×	1.2k 0.8×	567 0.6×	165 0.4×	433 1.2×	47	1.7k
RE Sobol United States	11	699 0.4×	681 0.5×	202 0.2×	164 0.4×	296 0.8×	15	1.1k
Tamara Intermesoli Italy	17	460 0.3×	575 0.4×	214 0.2×	109 0.2×	331 0.9×	46	1.0k
ER van Wering Netherlands	12	649 0.4×	719 0.5×	123 0.1×	238 0.5×	215 0.6×	16	1.1k
J R Downing United States	15	917 0.5×	880 0.6×	186 0.2×	338 0.7×	161 0.4×	19	1.4k
E. Renate Panzer-Grümayer Austria	14	692 0.4×	614 0.4×	149 0.2×	244 0.5×	167 0.5×	20	1.0k
GK Rivera United States	24	1.3k 0.7×	1.2k 0.8×	255 0.3×	427 0.9×	244 0.7×	41	1.9k

Countries citing papers authored by Rebecca Garris

Since Specialization

Citations

This map shows the geographic impact of Rebecca Garris's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rebecca Garris with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rebecca Garris more than expected).

Fields of papers citing papers by Rebecca Garris

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rebecca Garris. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rebecca Garris. The network helps show where Rebecca Garris may publish in the future.

Co-authorship network of co-authors of Rebecca Garris

This figure shows the co-authorship network connecting the top 25 collaborators of Rebecca Garris. A scholar is included among the top collaborators of Rebecca Garris based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rebecca Garris. Rebecca Garris is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kantarjian, Hagop M., Elias Jabbour, Nicholas J. Short, et al.. (2025). Treatment‐free remission in nontransplanted patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia. Cancer. 131(5). e35773–e35773. 4 indexed citations

Kantarjian, Hagop M., Nitin Jain, Jayastu Senapati, et al.. (2025). Long-term outcomes of a chemotherapy-free regimen of concomitant blinatumomab and inotuzumab ozogamicin in older patients with Philadelphia negative B-cell acute lymphoblastic leukemia. Blood. 146(Supplement 1). 5131–5131.

Kantarjian, Hagop M., Nitin B. Jain, Fadi Haddad, et al.. (2025). A comprehensive analysis of PCR for BCR::ABL1 and next-generation sequencing (NGS)-based measurable residual disease (MRD) with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL): Prevalence, association with transcript type, and clinical outcomes. Blood. 146(Supplement 1). 551–551.

Kantarjian, Hagop, Koji Sasaki, Nitin B. Jain, et al.. (2025). Hyper-CVAD versus hyper-CVAD plus blinatumomab for adult patients with newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis. Blood. 146(Supplement 1). 1566–1566.

Kantarjian, Hagop M., Nicholas J. Short, Fadi Haddad, et al.. (2024). Results of the Simultaneous Combination of Ponatinib and Blinatumomab in Philadelphia Chromosome-Positive ALL. Journal of Clinical Oncology. 42(36). 4246–4251. 23 indexed citations

Ravandi, Farhad, Jayastu Senapati, Nitin B. Jain, et al.. (2024). Longitudinal follow up of a phase 2 trial of venetoclax added to hyper-CVAD, nelarabine and pegylated asparaginase in patients with T-cell acute lymphoblastic leukemia and lymphoma. Leukemia. 38(12). 2717–2721. 8 indexed citations

Short, Nicholas J., Nitin Jain, Jayastu Senapati, et al.. (2024). ALL-808 Very Promising Results of the Dose Dense (D-D) Mini-Hyper-CVD-Inotuzumab-Blinatumomab Phase 2 Trial in Patients with Relapsed-Refractory Acute Lymphoblastic Leukemia. Clinical Lymphoma Myeloma & Leukemia. 24. S284–S285. 6 indexed citations

Senapati, Jayastu, Elias Jabbour, Nicholas J. Short, et al.. (2024). Chemotherapy Free Regimen of Inotuzumab Ozogamicin and Blinatumomab in Frontline Therapy of Older Patients with Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia. Blood. 144(Supplement 1). 1442–1442. 3 indexed citations

Short, Nicholas J., Elias Jabbour, Nitin Jain, et al.. (2023). S118: A CHEMOTHERAPY-FREE COMBINATION OF PONATINIB AND BLINATUMOMAB FOR PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA: SUBGROUP ANALYSIS FROM A PHASE II STUDY. HemaSphere. 7(S3). e4968152–e4968152. 2 indexed citations

10.

Kantarjian, Hagop M., Nicholas J. Short, Nitin Jain, et al.. (2023). Frontline combination of ponatinib and hyper‐CVAD in Philadelphia chromosome‐positive acute lymphoblastic leukemia: 80‐months follow‐up results. American Journal of Hematology. 98(3). 493–501. 45 indexed citations

11.

Jabbour, Elias, Nicholas J. Short, Nitin Jain, et al.. (2022). Blinatumomab is associated with favorable outcomes in patients with B‐cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10⁻⁴ and higher. American Journal of Hematology. 97(9). 1135–1141. 23 indexed citations

12.

Sasaki, Yuya, Hagop M. Kantarjian, Nicholas J. Short, et al.. (2022). Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib. Leukemia. 36(5). 1253–1260. 17 indexed citations

13.

Richard‐Carpentier, Guillaume, Hagop M. Kantarjian, Guilin Tang, et al.. (2021). Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: the MD Anderson experience. Blood Advances. 5(23). 5415–5419. 25 indexed citations

14.

Short, Nicholas J., Hagop M. Kantarjian, Keyur P. Patel, et al.. (2020). Ultrasensitive Next-Generation Sequencing-Based Measurable Residual Disease Assessment in Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia after Frontline Therapy: Correlation with Flow Cytometry and Impact on Clinical Outcomes. Blood. 136(Supplement 1). 26–28. 5 indexed citations

15.

Jabbour, Elias, Koji Sasaki, Farhad Ravandi, et al.. (2019). Inotuzumab ozogamicin in combination with low‐intensity chemotherapy (mini‐HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome‐negative acute lymphoblastic leukemia: A propensity score analysis. Cancer. 125(15). 2579–2586. 66 indexed citations

16.

Sasaki, Yuya, Nicholas J. Short, Hagop M. Kantarjian, et al.. (2019). Prognostic Significance of IKZF1, PAX5, and CDKN2A Deletions in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated with Hyper-CVAD/MA with Dasatinib or Ponatinib. Blood. 134(Supplement_1). 2753–2753. 2 indexed citations

17.

Jabbour, Elias, Kathryn G. Roberts, Koji Sasaki, et al.. (2019). Inotuzumab Ozogamicin (Ino) May Overcome the Impact of Philadelphia Chromosome (Ph)-like Phenotype in Adult Patients (pts) with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL). Blood. 134(Supplement_1). 1641–1641. 9 indexed citations

18.

Jabbour, Elias, Nicholas J. Short, Farhad Ravandi, et al.. (2018). Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study. The Lancet Haematology. 5(12). e618–e627. 160 indexed citations

19.

Jabbour, Elias, Susan O’Brien, Deborah A. Thomas, et al.. (2015). Inotuzumab Ozogamicin (IO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) as Frontline Therapy for Older Patients (pts) and as Salvage Therapy for Adult with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL). Clinical Lymphoma Myeloma & Leukemia. 15. S171–S171. 6 indexed citations

20.

Jabbour, Elias, Susan O’Brien, Deborah A. Thomas, et al.. (2014). Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) As Frontline Therapy for Older Patients (≥60 years) with Acute Lymphoblastic Leukemia (ALL). Blood. 124(21). 794–794. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact